Literature DB >> 33259961

Nanoparticles target intimal macrophages in atherosclerotic lesions.

Chathurika S Dhanasekara1, Jia Zhang1, Shufang Nie1, Guigen Li2, Zhaoyang Fan3, Shu Wang4.   

Abstract

Oxidized phosphatidylcholines (oxPCs) enriched on the oxidized LDL (oxLDL) surface are responsible ligands for binding oxLDL to the CD36 receptor of intimal macrophages in atherosclerotic lesions. We synthesized liposome-like nanoparticles (NPs) using soy phosphatidylcholine and incorporated 1-palmitoyl-2-(4-keto-dodec-3-enedioyl) phosphatidylcholine, a type of oxPCs, on their surface to make ligand-NP (L-NPs). The objectives of this study were to measure and compare their binding affinity to and uptake by primary mouse and THP-1 derived macrophages, and to determine their target specificity to intimal macrophages in aortic lesions in LDL receptor null (LDLr-/-) mice. All in vitro data demonstrate that L-NPs had a high binding affinity to macrophage CD36 receptor. L-NPs had 1.4-fold higher accumulation in aortic lesion areas than NPs. L-NPs co-localized with intimal macrophages and CD36 receptors in the aortic lesions. This target delivery approach may portend a breakthrough in molecular imaging and targeted treatment of atherosclerosis.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1-Palmitoyl-2-(4-keto-dodec-3-enedioyl) phosphatidylcholine; Atherosclerosis; CD36 receptors; Macrophages; Nanoparticles; Targeted delivery

Mesh:

Substances:

Year:  2020        PMID: 33259961      PMCID: PMC8514141          DOI: 10.1016/j.nano.2020.102346

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  59 in total

Review 1.  The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  J Lipid Res       Date:  2008-12-11       Impact factor: 5.922

Review 2.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

3.  Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species.

Authors:  E A Podrez; M Febbraio; N Sheibani; D Schmitt; R L Silverstein; D P Hajjar; P A Cohen; W A Frazier; H F Hoff; S L Hazen
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 4.  Inflammation and its resolution as determinants of acute coronary syndromes.

Authors:  Peter Libby; Ira Tabas; Gabrielle Fredman; Edward A Fisher
Journal:  Circ Res       Date:  2014-06-06       Impact factor: 17.367

5.  Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging.

Authors:  M E Kooi; V C Cappendijk; K B J M Cleutjens; A G H Kessels; P J E H M Kitslaar; M Borgers; P M Frederik; M J A P Daemen; J M A van Engelshoven
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

Review 6.  Plaque stabilization: Can we turn theory into evidence?

Authors:  Peter Libby; William Sasiela
Journal:  Am J Cardiol       Date:  2006-10-02       Impact factor: 2.778

Review 7.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

8.  A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.

Authors:  Eugene A Podrez; Eugenia Poliakov; Zhongzhou Shen; Renliang Zhang; Yijun Deng; Mingjiang Sun; Paula J Finton; Lian Shan; Maria Febbraio; David P Hajjar; Roy L Silverstein; Henry F Hoff; Robert G Salomon; Stanley L Hazen
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

Review 9.  CD36 and macrophages in atherosclerosis.

Authors:  Sophie Collot-Teixeira; Juliette Martin; Chris McDermott-Roe; Robin Poston; John Louis McGregor
Journal:  Cardiovasc Res       Date:  2007-03-14       Impact factor: 10.787

10.  Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles.

Authors:  Shufang Nie; Jia Zhang; Raul Martinez-Zaguilan; Souad Sennoune; Md Nazir Hossen; Alice H Lichtenstein; Jun Cao; Gary E Meyerrose; Ralph Paone; Suthipong Soontrapa; Zhaoyang Fan; Shu Wang
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

View more
  2 in total

Review 1.  Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations.

Authors:  Isabella Hetherington; Hana Totary-Jain
Journal:  Mol Ther       Date:  2022-09-05       Impact factor: 12.910

2.  Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.

Authors:  Dasia Aldarondo; Elizabeth Wayne
Journal:  Adv Drug Deliv Rev       Date:  2022-01-24       Impact factor: 17.873

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.